Source: Annual Congress 2011 - Mechanism and monitoring of airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Bafadhel, S. McKenna, S. Terry, V. Mistry, M. Pancholi, D. Lomas, P. Venge, M. Barer, S. Johnston, I. Pavord, C. Brightling (Leicester, London, Cambridge, United Kingdom; Uppsala, Sweden). Sputum eosinophilia identifies systemic corticosteroid responsiveness in acute exacerbations of COPD. Eur Respir J 2011; 38: Suppl. 55, 354

Member's Comments

No comment yet.

Related content which might interest you: Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma Source: Eur Respir J 2005; 25: 41-46 Year: 2005 Utility of aerosolized budesonide therapy in acute moderate exacerbations of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 283s Year: 2003 Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006 Relationship between systemic inflammation and rhythmicity of acute exacerbations of COPD Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases Year: 2021 The role of nebulised budesonide in the treatment of exacerbations of COPD Source: Eur Respir J 2007; 29: 660-667 Year: 2007 Adherence with inhaled respiratory therapeutics is associated with reduced acute exacerbations of chronic obstructive pulmonary disease Source: Annual Congress 2011 - COPD: integrated care and rehabilitation Year: 2011 The association between airway and systemic eosinophilia and symptoms and exacerbations differ between asthma and COPD patients Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling Year: 2020 Assessment and evaluation of symptomatic steroid-naive asthmatics without sputum eosinophilia and their response to inhaled corticosteroids Source: Eur Respir J 2002; 20: 1364-1369 Year: 2002 Outcome of COPD exacerbations treated with and without oral steroids in relation to airway and systemic inflammation Source: Eur Respir J 2005; 26: Suppl. 49, 283s Year: 2005 Sputum eosinophilia and the response to inhaled corticosteroid (mometasone) in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 62s Year: 2004 Aerosolized budesonide therapy in acute moderate exacerbations of Indian asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 343s Year: 2004 Nebulized therapy in bronchial asthma exacerbation Source: Eur Respir J 2002; 20: Suppl. 38, 52s Year: 2002 Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 146s Year: 2001 Cytokine profile in sputum from non-infective exacerbation of COPD and non-atopic asthma Source: Eur Respir J 2002; 20: Suppl. 38, 252s Year: 2002 Breath glucose measurements in asthma and alveolitis patients during exacerbation and after steroids Source: Annual Congress 2007 - Noninvasive evaluation of airway diseases Year: 2007 Chronic rhinosinusitis and airway inflammation in new onset asthma in adults Source: Annual Congress 2011 - Asthma mechanisms Year: 2011 The role of nebulised budesonide in the treatment of acute exacerbations of COPD Source: Eur Respir J 2007; 30: 399-400 Year: 2007 Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Follow-up of sputum eosinophils and cytokines during and out of exacerbations in severe refractory asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 594s Year: 2004 Sputum biomarkers in COPD exacerbations Source: Annual Congress 2011 - Monitoring exacerbations of airway diseases Year: 2011